Moderna RSV vaccine efficacy declining quicker than peers’, says TD Cowen

TD Cowen analyst Tyler Van Buren says longer follow-up from the Phase 3 mRNA-1345 trial at ReSViNET suggests that Moderna’s (MRNA) RSV vaccine efficacy is declining quicker than the GSK (GSK) and Pfizer (PFE) vaccines. While noting the comparison of slightly different endpoints, the firm is concerned this could negatively affect mRNA-1345’s profile if confirmed with additional data. The firm has a Market Perform rating and $75 price target on Moderna shares.